List of Excipients in Branded Drug PLERIXAFOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fresenius Kabi Usa LLC	PLERIXAFOR	plerixafor	65219-284	HYDROCHLORIC ACID
Fresenius Kabi Usa LLC	PLERIXAFOR	plerixafor	65219-284	SODIUM CHLORIDE
Fresenius Kabi Usa LLC	PLERIXAFOR	plerixafor	65219-284	SODIUM HYDROXIDE
Fresenius Kabi Usa LLC	PLERIXAFOR	plerixafor	65219-284	WATER

Generic Drugs Containing PLERIXAFOR

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	plerixafor	0480-4320	HYDROCHLORIC ACID
Teva Pharmaceuticals Inc	plerixafor	0480-4320	SODIUM CHLORIDE
Teva Pharmaceuticals Inc	plerixafor	0480-4320	SODIUM HYDROXIDE
Teva Pharmaceuticals Inc	plerixafor	0480-4320	WATER

What are the Most Frequently-Used Excipients in PLERIXAFOR?

# Of NDCs	Excipient
11	HYDROCHLORIC ACID
11	SODIUM CHLORIDE
11	SODIUM HYDROXIDE
11	WATER

Last updated: August 8, 2026

Plerixafor’s commercial opportunity is concentrated in manufacturing efficiency, container-closure performance, ready-to-use presentation, and supply reliability rather than in complex excipient innovation. The reference product, Mozobil, is a simple preservative-free aqueous injection containing plerixafor, sodium chloride, hydrochloric acid, sodium hydroxide, and water for injection. Generic competition has reduced the value of the active pharmaceutical ingredient monopoly, while hospital demand remains tied to autologous stem-cell mobilization in lymphoma and multiple myeloma.

Plerixafor Excipient Strategy and Commercial Opportunities

What is the current formulation of plerixafor?

Plerixafor is marketed as a sterile, preservative-free, aqueous solution for subcutaneous injection at a concentration of 20 mg/mL. The U.S. reference product is supplied in a single-use vial containing 1.2 mL of solution, equivalent to 24 mg of plerixafor per vial [1].

Formulation attribute	Mozobil reference profile
Active ingredient	Plerixafor
Strength	20 mg/mL
Dosage form	Sterile injectable solution
Route	Subcutaneous injection
Primary excipient	Sodium chloride
pH adjustment	Hydrochloric acid and sodium hydroxide
Vehicle	Water for injection
Preservative	None
Container	Single-use glass vial
Typical dose	0.24 mg/kg, subject to renal-dose adjustment
Maximum labeled dose	40 mg
Storage	Controlled room-temperature conditions

The formulation is intentionally simple. Plerixafor is administered in a clinical setting, the injection volume is small, and the product does not require a prolonged multidose-use period. These characteristics reduce the need for antimicrobial preservatives, surfactants, complex buffering systems, or lyophilization.

Which excipients are most important for plerixafor injection?

Sodium chloride

Sodium chloride is the principal functional excipient. Its role is to adjust osmolality and improve subcutaneous tolerability. A near-isotonic formulation reduces the risk of injection-site discomfort and local tissue irritation.

The commercial value of sodium chloride in this product is low on a per-vial basis, but its quality attributes remain important. Suppliers must provide injectable-grade material with controlled elemental impurities, endotoxin, bioburden, and particulate levels. Pharmaceutical manufacturers may qualify multiple suppliers because sodium chloride is inexpensive and globally available.

Hydrochloric acid and sodium hydroxide

Hydrochloric acid and sodium hydroxide are used for pH adjustment rather than as a conventional buffer pair. This approach minimizes the number of formulation components and avoids introducing additional counterions or buffer species.

A pH-adjustment strategy can simplify regulatory justification, but the manufacturing process must control:

• Final pH
• Buffer capacity
• Degradation during sterilization
• Glass or elastomer interaction
• Subvisible particles
• Long-term pH drift

The absence of a conventional buffer can create less formulation redundancy. Small changes in raw-material quality, water quality, or process conditions may have a greater impact on final pH.

Water for injection

Water for injection is the principal vehicle and must meet compendial requirements for conductivity, total organic carbon, microbial control, and endotoxin. Because the product is a low-volume parenteral, water-system qualification and aseptic processing remain central to commercial reliability.

Preservatives and surfactants

The reference formulation does not require a preservative. A preservative would add toxicological, compatibility, and labeling burdens without a clear commercial benefit for a single-use vial.

Surfactants also appear unnecessary for the reference presentation. A surfactant could become relevant if a developer pursues a higher-concentration formulation, a prefilled syringe, a polymeric container, or a formulation intended to reduce adsorption. Such changes would require extractables, leachables, particulate, and stability studies.

What excipient strategy is best for generic plerixafor?

The strongest generic strategy is an in-kind formulation with controlled manufacturing cost. A developer should generally prioritize formulation sameness, supply resilience, and container compatibility over speculative excipient differentiation.

Strategic option	Commercial value	Technical risk	Regulatory burden
Reference-like sodium chloride formulation	High	Low	Low
Alternative isotonic agent	Moderate	Moderate	Moderate
Buffered formulation	Low to moderate	Moderate	Moderate
Preserved multidose vial	Low	High	High
Prefilled syringe	Moderate	Moderate to high	High
Higher-concentration injection	Moderate	High	High
Lyophilized product	Low to moderate	High	High
Ready-to-use institutional presentation	High	Moderate	Moderate

A generic manufacturer should avoid unnecessary departures from the reference product. A change from sodium chloride to another tonicity agent, such as dextrose or mannitol, may be technically feasible but creates new questions involving osmolality, local tolerability, degradation, and comparative pharmaceutical equivalence.

The preferred development sequence is:

1. Match the reference concentration and pH range.
2. Use compendial sodium chloride and water for injection.
3. Establish a robust pH-adjustment process.
4. Qualify a low-adsorption glass vial and elastomer closure.
5. Demonstrate sterility, particulate control, extractables, leachables, and container-closure integrity.
6. Evaluate terminal sterilization only if product stability supports it.
7. Preserve the single-use, preservative-free presentation.

What formulations are protected by plerixafor patents?

Plerixafor is a small-molecule drug, so it is subject to conventional generic-drug competition rather than biosimilar competition. The original patent estate covered the bicyclam chemical class and therapeutic use of CXCR4 antagonists, including stem-cell mobilization. The commercial importance of those rights has declined as core exclusivity periods have expired or approached expiration.

The most relevant U.S. patent categories are:

Patent category	Commercial relevance
Chemical compound patents	Protected the plerixafor molecule and related bicyclam structures
Stem-cell mobilization method patents	Covered use with granulocyte colony-stimulating factor and collection of hematopoietic stem cells
Formulation patents	Potentially covered injectable compositions, concentration, pH, or stability attributes
Manufacturing patents	Could cover synthesis, purification, crystallization, or impurity control
Pediatric exclusivity	Temporary regulatory extension, where granted

The Orange Book is the controlling public source for listed U.S. patents and regulatory exclusivity associated with approved drug products [2]. A current ANDA applicant must evaluate any remaining listed patent, certification requirement, and litigation risk rather than relying on the original Mozobil patent history.

Are there formulation patents that block generic plerixafor?

A formulation patent would present a greater risk if it covered the exact 20 mg/mL aqueous composition, a mandatory pH range, or a necessary container-closure configuration. In practice, a generic developer can often design around narrow formulation claims by changing nonessential excipients or process parameters, provided the resulting product remains pharmaceutically equivalent.

The highest-risk formulation claims would be those that:

• Recite plerixafor at a defined concentration
• Require sodium chloride within a specified range
• Limit pH to a narrow interval
• Claim a particular degradation-control profile
• Cover a specific vial, stopper, or syringe system
• Link the formulation to long-term room-temperature stability

The practical patent question is not whether plerixafor has any historical patent coverage. It is whether an unexpired, enforceable claim reads on the proposed generic composition, manufacturing process, or labeled use.

When does plerixafor lose exclusivity?

Plerixafor’s original U.S. regulatory exclusivity has expired, and generic versions have entered the market. The relevant commercial exclusivity framework now consists of remaining patent rights, ANDA timing, manufacturing capacity, and contracting relationships.

Exclusivity element	Current commercial effect
New chemical entity exclusivity	Expired
Original compound patents	Generally expired or no longer a primary barrier
Method-of-use patents	Must be reviewed claim by claim
Formulation patents	Potentially relevant if unexpired and listed
Pediatric exclusivity	Historical, if applicable
Orphan-drug status	Relevant to original approval period, not a permanent barrier
Generic competition	Present in the U.S. market

Mozobil was approved by the FDA in December 2008 for use with G-CSF to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma [1]. The approval was based on a targeted hospital and transplant-center market rather than a broad chronic-treatment market.

What is the Orange Book status of plerixafor?

The Orange Book identifies approved drug products, reference-listed drugs, patent information, and regulatory exclusivity data for FDA-approved medicines [2]. For plerixafor, the commercial review should distinguish between:

• The reference-listed drug, Mozobil
• Approved plerixafor injection ANDAs
• Any currently listed patents
• Paragraph IV certifications
• Label carve-outs for protected methods of use
• Therapeutic-equivalence ratings

Because plerixafor is an injectable small molecule, an ANDA applicant must establish pharmaceutical equivalence and bioequivalence through the applicable FDA pathway. A standard systemic bioequivalence approach may not resemble oral-product studies. The applicant must follow FDA product-specific guidance and demonstrate that the generic has the same active ingredient, strength, dosage form, route, and essential formulation characteristics [3].

Which companies are challenging the plerixafor market?

Generic injectable manufacturers are the primary challengers. The market is open to companies with:

• Sterile injectable manufacturing capacity
• A reliable supply of plerixafor API
• Experience with low-volume parenterals
• Hospital and specialty-distributor contracts
• FDA-compliant aseptic processing
• Capacity to maintain supply during transplant-season demand spikes

Potential competitors include established generic injectable companies, contract manufacturing organizations, and regional suppliers seeking hospital tenders. The relevant competitive advantage is unlikely to come from a novel excipient. It will come from lower cost of goods, reliable fill-finish capacity, low shortage risk, and favorable contracting.

What Paragraph IV challenges affect plerixafor?

Paragraph IV risk depends on the patents listed for the reference product when an ANDA is filed. An applicant may certify that a listed patent is invalid, unenforceable, or not infringed. If the patent holder initiates litigation within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court action [4].

For plerixafor, the most credible Paragraph IV theories would target:

• Expired or improperly listed method-of-use patents
• Narrow formulation claims
• Lack of written description or enablement
• Obviousness of an isotonic aqueous injection
• Noninfringement through an alternative excipient or process
• Patent-term expiration

The absence of a complex delivery system reduces formulation-litigation exposure. A generic developer still must conduct a claim chart covering formulation, use, synthesis, and manufacturing patents.

What manufacturing and IP barriers affect plerixafor?

Sterile manufacturing

Sterile manufacturing is the main operational barrier. Plerixafor’s excipients are inexpensive, but the finished product requires validated aseptic processing, sterile filtration or sterilization, vial filling, inspection, and container-closure integrity testing.

Key manufacturing risks include:

• Bioburden before sterilizing filtration
• Filter compatibility and adsorption
• Visible and subvisible particles
• Fill-volume accuracy
• Stopper coring
• Glass delamination
• Plunger or stopper extractables
• Stability after transport
• Batch rejection from sterility failures

API supply

Plerixafor synthesis involves a complex bicyclam structure and requires control of related substances, residual solvents, elemental impurities, and potentially difficult purification steps. API cost can therefore have a greater effect on gross margin than excipient cost.

A dual-source strategy for API and critical packaging components can reduce supply risk. A generic company with internal API manufacturing may have a cost advantage, but it also assumes greater regulatory and process-validation responsibility.

Container-closure systems

The reference vial is difficult to displace on cost but may be less convenient than a prefilled syringe. A prefilled product could reduce preparation steps in transplant centers, although it would create additional compatibility and device requirements.

Commercially relevant container opportunities include:

• Low-sorptive glass vials
• Ready-to-administer syringes
• Unit-dose packaging
• Tamper-evident institutional packs
• Barcoded cartons for pharmacy automation
• Small-volume vial configurations that reduce wastage

What commercial opportunities exist for plerixafor excipients?

The excipient opportunity is modest in molecule economics but meaningful in platform strategy.

Ready-to-use presentations

A prefilled syringe or ready-to-administer unit could appeal to hospitals seeking to reduce pharmacy preparation time and dosing errors. The opportunity is strongest if the device can maintain the existing 20 mg/mL concentration without introducing silicone oil, tungsten, adhesive, or elastomer-related impurities.

Higher-concentration products

A higher-concentration formulation could reduce injection volume and packaging waste. The clinical value is limited because the reference injection volume is already small. Higher concentration would require new work on solubility, pH, osmolality, local tolerability, precipitation, and stability.

Improved stability

A formulation with greater resistance to temperature excursions could support international distribution and reduce product loss. The existing room-temperature presentation already limits the commercial need for refrigerated logistics, so the value of a stability-enhancing excipient must be demonstrated against development cost.

Lyophilized dosage forms

A lyophilized vial could improve long-term stability but would add reconstitution steps, increase manufacturing cost, and reduce convenience. It is unlikely to outperform a stable liquid formulation unless a specific instability problem emerges.

Hospital-use packaging

Packaging and workflow improvements may generate more value than new excipients. Unit-dose cartons, syringe-ready formats, and low-waste vial sizes can support hospital purchasing decisions without changing the active formulation.

How does plerixafor compare with competing stem-cell mobilization products?

Plerixafor is used as an adjunct to G-CSF, not as a replacement for all mobilization regimens. Competing approaches include G-CSF alone, chemotherapy plus G-CSF, and newer mobilization strategies under development.

Product or approach	Role	Excipient opportunity	Competitive pressure
Plerixafor injection	Rapid CXCR4-antagonist mobilization	Ready-to-use injectable formats	Generic price erosion
Filgrastim or pegfilgrastim	Backbone mobilization therapy	Prefilled syringes and biologic stability	Established use and lower-cost alternatives
Chemotherapy plus G-CSF	Mobilization in selected patients	Infusion workflow and supportive care	More toxicity and logistical complexity
Biosimilar G-CSF	Lower-cost biologic comparator	Device and cold-chain optimization	Indirect pressure on plerixafor use

Plerixafor has no biosimilar risk because it is a chemically synthesized small molecule. Its risk is generic substitution and possible reduction in use if transplant centers adopt alternative mobilization protocols.

What regulatory status applies to plerixafor?

FDA approval covers plerixafor with G-CSF for mobilization of hematopoietic stem cells for collection and autologous transplantation in adults with non-Hodgkin lymphoma or multiple myeloma. The FDA label includes renal-dose adjustment for patients with severe renal impairment and weight-based pediatric dosing provisions [1].

A generic product must address:

• Pharmaceutical equivalence
• Sterility and endotoxin
• Injectable particulate control
• Container-closure integrity
• Stability through the proposed expiry period
• Labeling consistency
• Dose-delivery accuracy
• Product-specific FDA requirements

The European Medicines Agency and national European regulators apply comparable principles for sterile injectable quality, although approval routes, reference-product requirements, and national tender dynamics differ [5].

What generic launch risks exist for plerixafor?

The principal launch risks are commercial rather than scientific.

Risk	Likely impact
Multiple approved injectables	Rapid price compression
Limited transplant-center volume	Concentrated customer base
API supply interruption	High, because hospitals expect uninterrupted treatment
Sterile-filling failure	High
Hospital tender loss	High
Small vial-volume inefficiency	Moderate
Formulation patent challenge	Product-specific
Substitution limits	Moderate, depending on jurisdiction
Demand variability	Moderate

A successful launch should target transplant centers, specialty distributors, group purchasing organizations, and hospital systems. Supply continuity can justify a premium over the lowest-cost supplier, particularly where plerixafor is used for time-sensitive apheresis scheduling.

How strong is the patent estate for plerixafor?

The patent estate is materially weaker than that of a recently launched complex biologic or long-acting injectable. The reference product has a simple liquid formulation, no device-dependent mechanism, and no biosimilar pathway. Historical compound and use patents remain relevant to freedom-to-operate analysis, but the largest commercial barriers are likely to be sterile manufacturing, API quality, and contracting.

A practical strength assessment is:

Estate component	Relative strength
Original molecule protection	Low after expiration
Core stem-cell mobilization use	Low to moderate, depending on claim status
Simple aqueous formulation	Low to moderate
Device or delivery protection	Low
Manufacturing know-how	Moderate
Supply-chain capability	Moderate to high
Brand and hospital relationships	Moderate

Key Takeaways

• Plerixafor is a simple, preservative-free aqueous injection containing sodium chloride, pH-adjusting hydrochloric acid and sodium hydroxide, and water for injection.
• The best generic excipient strategy is close replication of the reference formulation.
• New excipients are unlikely to create substantial value unless they enable higher concentration, lower injection volume, improved stability, or a ready-to-use device.
• Sterile manufacturing, API purification, container compatibility, and supply reliability are more important than excipient differentiation.
• Plerixafor faces generic competition, not biosimilar competition.
• Orange Book and patent analysis should focus on any remaining method-of-use, formulation, and manufacturing claims.
• Prefilled syringes, unit-dose hospital packaging, and supply-assured products are the clearest commercial opportunities.
• The main launch risk is price erosion in a concentrated transplant-center market.

FAQs

Can plerixafor be formulated without sodium chloride?

Yes. Another tonicity agent could be used, but the developer would need to establish equivalent osmolality, injection-site tolerability, stability, and regulatory acceptability. Sodium chloride remains commercially preferred because it is familiar, inexpensive, and consistent with the reference product.

Is a buffered plerixafor injection commercially attractive?

Usually not. A conventional buffer may improve pH control but adds formulation complexity and new compatibility questions. Its value would depend on a demonstrated stability or tolerability advantage.

Could plerixafor be sold in a prefilled syringe?

Yes, subject to device compatibility, dose accuracy, extractables and leachables, silicone or lubricant control, sterility assurance, and human-factors requirements. The commercial benefit would be reduced preparation time rather than a major clinical improvement.

Is a lyophilized plerixafor product likely to replace the liquid vial?

Unlikely for routine use. Lyophilization could improve stability, but it would add reconstitution steps and cost while the existing liquid presentation is already operationally simple.

What is the strongest licensing opportunity around plerixafor?

The strongest opportunities are likely to involve regional commercialization rights, sterile fill-finish capacity, dual-source API supply, and ready-to-administer packaging. A standalone novel-excipient license is less compelling unless it supports a differentiated device or materially improves stability.

References

1. U.S. Food and Drug Administration. (2023). Mozobil (plerixafor injection) prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.

3. U.S. Food and Drug Administration. (2024). Product-specific guidance for generic drug development. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. FDA.

5. European Medicines Agency. (2024). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. EMA.